A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 201-216

  Wang, Gang ^a   McIntyre, Alexander ^b   Earley, Willie R ^c   Raines, Shane R ^c   Eriksson, Hans ^d  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Penticton Regional Hospital   (Canada)

^c ASTRAZENECA   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

Antidepressive agents (pharmacological action); Antipsychotic agents; Clinical trial; Phase III; Sustained release preparations; Treatment efficacy

Indexed keywords

ESCITALOPRAM; PLACEBO; QUETIAPINE;

ADULT; ARTHRALGIA; ARTICLE; CHILL; CONSTIPATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EVENING DOSAGE; EXTENDED RELEASE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; HYPERHIDROSIS; HYPERSOMNIA; INCREASED APPETITE; INFLUENZA; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PHASE 3 CLINICAL TRIAL; PITTSBURGH SLEEP QUALITY INDEX; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEXUAL DYSFUNCTION; SOMNOLENCE; SUICIDE ATTEMPT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; VOMITING; XEROSTOMIA;

EID: 84893473048     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S50248     Document Type: Article

References (42)

1. Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther. 2003;25(8):2289-2304.
2. Howland RH. Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Part 2: Study outcomes. J Psychosoc Nurs Ment Health Serv. 2008;46(10):21-24.
3. AstraZeneca Pharmaceuticals (Ireland). Seroquel XR: summary of product characteristics for Ireland. 2013. Available from: http://www.medicines.ie/medicine/13032/SPC. Accessed August 1, 2013.
4. AstraZeneca Pharmaceuticals. Once-daily Seroquel XR (quetiapine fumarate) extended-release tablets. 2012. Available from: http://www1.astrazeneca-us.com/pi/seroquelxr.pdf. Accessed July 9, 2012.
5. AstraZeneca Pharmaceuticals. Seroquel XR product monograph (Canada). 2011. Available from: http://www.astrazeneca.ca/documents/ProductPortfolio/SEROQUEL%20XR_PM_en.pdf. Accessed July 21, 2011.
6. AstraZeneca Pharmaceuticals. Seroquel XR Australian prescribing information. 2013. Available from: http://www1.astrazeneca-australia.com/pi/seroquelxr.pdf. Accessed.
7. Bortnick B, El-Khalili N, Banov M, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord. 2011;128(1-2):83-94.
8. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Åström M, Brecher M. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo-and duloxetine-controlled study. J Clin Psychiatry. 2009;70(4):526-539.
9. Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriksson H. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr. 2009;14(6):299-313.
10. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70(4): 540-549.
11. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010;13(7): 917-932.
12. Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety. 2010;27(10): 964-976.
13. Katila H, Mezhebovsky I, Mulroy A, et al. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry. 2013;21(8): 1769-1784.
14. Glick ID, Suppes T, DeBattista C, Hu RJ, Marder S. Psychopharmacologic treatment strategies for depression, bipolar disorder, and schizophrenia. Ann Intern Med. 2001;134(1):47-60.
15. AstraZeneca. Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder (AMBER). Available from: http://clinicaltrials.gov/ct2/show/NCT00351169. NLM identifier: NCT00351169. Accessed November 18, 2013.
16. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-33.
17. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
18. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
19. European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products (CPMP): Note for guidance on clinical investigation of medicinal products in the treatment of depression. 2002. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003526.pdf. Accessed November 6, 2013.
20. Forest Pharmaceuticals. Escitalopram prescribing information. 2009. Available from: http://www.frx.com/pi/lexapro_pi.pdf. Accessed November 6, 2013.
21. National Institute of Mental Health. CGI: clinical global impressions. In: Guy W, Bonato RR, editors. Manual for the ECDEU Assessment Battery. Rockville (MD): NIMH; 1970:1-6.
22. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.
23. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321-326.
24. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193-213.
25. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
26. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
27. Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull. 1997;33(4):731-745.
28. Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry. 2000;176:363-368.
29. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44(2):77-87.
30. Khan A, Schwartz K. Study designs and outcomes in antidepressant clinical trials. Essent Psychopharmacol. 2005;6(4):221-226.
31. Yang H, Cusin C, Fava M. Is there a placebo problem in antidepressant trials? Curr Top Med Chem. 2005;5(11):1077-1086.
32. Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72(3):115-127.
33. Kobak KA, Kane JM, Thase ME, Nierenberg AA. Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol. 2007;27(1): 1-5.
34. Vieta E, Pappadopulos E, Mandel FS, Lombardo I. Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study. Int J Neuropsychopharmacol. 2011;14(8):1017-1027.
35. Dunlop BW, Thase ME, Wun CC, et al. A meta-analysis of factors impacting detection of antidepressant efficacy in clinical trials: the importance of academic sites. Neuropsychopharmacology. 2012;37(13): 2830-2836.
36. Undurraga J, Baldessarini RJ. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology. 2012;37(4): 851-864.
37. Yildiz A, Vieta E, Tohen M, Baldessarini RJ. Factors modifying drug and placebo responses in randomized trials for bipolar mania. Int J Neuropsychopharmacol. 2011;14(7):863-875.
38. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009;19(1):34-40.
39. Posternak MA, Zimmerman M, Keitner GI, Miller IW. A reevaluation of the exclusion criteria used in antidepressant efficacy trials. Am J Psychiatry. 2002;159(2):191-200.
40. Stein DJ, Baldwin DS, Dolberg OT, Despiegel N, Bandelow B. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry. 2006;67(11):1741-1746.
41. US Food and Drug Administration. Antidepressant use in children, adolescents and adults. 2010. Available from: http://www.fda.gov/cder/drug/antidepressants/default.htm. Accessed May 1, 2011.
42. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601.